NCT07011173 Assistance Delivery and Muscle Coordination
| NCT ID | NCT07011173 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | The Catholic University of America |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-11-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2024-11-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The experiment will be conducted with 15 chronic stroke survivors and 15 control subjects. Subjects will perform extension movements of the index finger of their more-impaired (stroke) or nondominant (control) hand under two different assistance types: end-effector assistance and exotendon assistance. For each assistance type, unassisted movements will be performed before and after the assistance. Subjects will be randomly assigned into two groups (A and B), who will receive the assistance in a different order. The finger movements and muscle activation patterns will be recorded during movements.
Eligibility Criteria
Inclusion Criteria for stroke survivors: * Age: 18 - 70 years old * First-ever unilateral cortical stroke with resultant hemiparesis at least 6 months prior to the experimental testing * Fugl-Meyer Upper Extremity Section 31 - 55 Exclusion Criteria for both stroke and control: * Presence of concurrent severe medical illness * Pain in hand or arm with movements * Loss of voluntary control of fingers and thumb * Inability to provide informed consent * Musculoskeletal injuries (e.g., fracture) or medical complications (e.g., severe cardiovascular disease).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07011173 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07011173 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07011173 currently recruiting?
Yes, NCT07011173 is actively recruiting participants. Contact the research team at leesw@cua.edu for enrollment information.
Where is the NCT07011173 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT07011173 clinical trial?
NCT07011173 is sponsored by The Catholic University of America. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.